Abilify Maintena
Schizophrenia, Bipolar I Disorder
CommercialMarketed
Key Facts
About Otsuka Holdings
Otsuka Holdings Co., Ltd. is a multinational pharmaceutical and healthcare company founded in 1964, headquartered in Tokyo, Japan. The company has built a strong reputation in central nervous system disorders, with major commercial successes including the antipsychotic Abilify and depression treatment Rexulti. Otsuka operates globally with a focus on innovation in psychiatry, neurology, oncology, and nephrology, maintaining a robust pipeline of novel therapeutics and a commitment to addressing unmet medical needs.
View full company profileTherapeutic Areas
Other Schizophrenia, Bipolar I Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| Abilify Maintena (aripiprazole) | Lundbeck | Approved/Commercial |